



WARF STATISTICS

50 Years of Technology Transfer

| | <u>TOTAL</u> | <u>IPA (7 yrs.) DHEW</u> |
|---|--------------|-------------------------------|
| Disclosures | 1,702 | |
| U. S. Pat. Apps. filed | 415 | 44 |
| U. S. Patents Issued | 270 | |
| U. S. Patents Unexpired | 146 | |
| U. S. Pat. Apps. Pending | 47 | |
| Inventions (Groups of Related Inventions) | 195 | 17 |
| Licensed Inventions | 62 | 7 |
| Inventions Producing or Produced Royalty Income | 43 | |
| No. Licensees | 71 | 18 |

By back calculating from the royalty rate, it can be estimated that all of WARF's licensees have collectively enjoyed \$1.75 billion of sales under license.

By way of contrast, in the last six months of 1975, one licensee sold 12.9 grams of oligomycin to 253 customers in 33 countries in a total of 477 orders. No royalty to WARF.

Oligomycin is unique in its ability to specifically block one step in oxidative phosphorylation, thus is in demand by diagnosticians and researchers everywhere. (All forms of life depend upon oxidative phosphorylation.)